“COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s58. doi:10.25251/skin.5.supp.58.